| Title |
PARP inhibitors
|
|---|---|
| Published in |
Hereditary Cancer in Clinical Practice, January 2015
|
| DOI | 10.1186/s13053-014-0024-8 |
| Pubmed ID | |
| Authors |
Maheen Anwar, Hafiz Muhammad Aslam, Shahzad Anwar |
| Abstract |
Poly (ADP-ribose) polymerases, abbreviated as PARPs, are a group of familiar proteins that play a central role in DNA repair employing the base excision repair (BER) pathway. There about 17 proteins in this family out of which the primary nuclear PARPs are PARP-1, PARP-2, PARP-3, and tankyrases 1 and 2 (PARP-5a and -5b) .The PARP family members are known to engage in a wide range of cellular activities, for example, DNA repair, transcription, cellular signaling, cell cycle regulation and mitosis amongst others. The chief functional units of PARP-1 are an amino terminal DNA binding domain (DBD), a central auto modification domain (AMD), and a carboxyl-terminal catalytic domain (CD). PARP inhibitors are currently undergoing clinical trials as targeted treatment modalities of breast, uterine, colorectal and ovarian cancer. This review summarizes current insights into the mechanism of action of PARP inhibitors, its recent clinical trials, and potential next steps in the evaluation of this promising class of anti-cancer drugs. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 61 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 61 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 11 | 18% |
| Researcher | 10 | 16% |
| Student > Ph. D. Student | 9 | 15% |
| Student > Master | 5 | 8% |
| Student > Doctoral Student | 4 | 7% |
| Other | 6 | 10% |
| Unknown | 16 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 14 | 23% |
| Biochemistry, Genetics and Molecular Biology | 12 | 20% |
| Agricultural and Biological Sciences | 9 | 15% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 8% |
| Chemistry | 2 | 3% |
| Other | 2 | 3% |
| Unknown | 17 | 28% |
Attention Score in Context
This research output has an Altmetric Attention Score of 13. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 May 2015.
All research outputs
#2,811,008
of 25,371,288 outputs
Outputs from Hereditary Cancer in Clinical Practice
#11
of 260 outputs
Outputs of similar age
#38,331
of 359,700 outputs
Outputs of similar age from Hereditary Cancer in Clinical Practice
#1
of 6 outputs
Altmetric has tracked 25,371,288 research outputs across all sources so far. Compared to these this one has done well and is in the 88th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 260 research outputs from this source. They receive a mean Attention Score of 4.8. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 359,700 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 89% of its contemporaries.
We're also able to compare this research output to 6 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them